A SARS-CoV-2 mRNA Vaccine - Preliminary Report
- PMID: 32813940
- DOI: 10.1056/NEJMc2026616
A SARS-CoV-2 mRNA Vaccine - Preliminary Report
Comment in
-
A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.N Engl J Med. 2020 Sep 17;383(12):1191-1192. doi: 10.1056/NEJMc2026616. Epub 2020 Aug 19. N Engl J Med. 2020. PMID: 32813942 No abstract available.
Comment on
-
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. N Engl J Med. 2020. PMID: 32663912 Free PMC article. Clinical Trial.
Similar articles
-
A SARS-CoV-2 mRNA Vaccine - Preliminary Report.N Engl J Med. 2020 Sep 17;383(12):1191. doi: 10.1056/NEJMc2026616. Epub 2020 Aug 19. N Engl J Med. 2020. PMID: 32813941 No abstract available.
-
A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.N Engl J Med. 2020 Sep 17;383(12):1191-1192. doi: 10.1056/NEJMc2026616. Epub 2020 Aug 19. N Engl J Med. 2020. PMID: 32813942 No abstract available.
-
COVID-19 and mRNA Vaccines-First Large Test for a New Approach.JAMA. 2020 Sep 22;324(12):1125-1127. doi: 10.1001/jama.2020.16866. JAMA. 2020. PMID: 32880613 No abstract available.
-
Development of vaccines for SARS-CoV-2.F1000Res. 2020 Aug 17;9:F1000 Faculty Rev-991. doi: 10.12688/f1000research.25998.1. eCollection 2020. F1000Res. 2020. PMID: 32850116 Free PMC article. Review.
-
Next-generation vaccine platforms for COVID-19.Nat Mater. 2020 Aug;19(8):810-812. doi: 10.1038/s41563-020-0746-0. Nat Mater. 2020. PMID: 32704139 Review. No abstract available.
Cited by
-
Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.J Big Data. 2022;9(1):92. doi: 10.1186/s40537-022-00643-x. Epub 2022 Jul 14. J Big Data. 2022. PMID: 35855914 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous